Peroxisome Proliferator-Activated Receptors in HCV-Related Infection

被引：20

作者：

Dharancy, Sebastien ^{[1
]}

Lemoine, Maud ^{[2
]}

Mathurin, Philippe ^{[1
]}

Serfaty, Lawrence ^{[2
]}

Dubuquoy, Laurent ^{[1
]}

机构：

[1] Univ Lille 2, CHRU Lille, Hop Huriez, Serv Malad Appareil Digestif & Nutr,INSERM,U795, F-59037 Lille, France

[2] Univ Paris 06, Hop St Antoine, AP HP, Serv Hepatol,Fac Med,INSERM,U680, F-75012 Paris, France

来源：

PPAR RESEARCH | 2009年 / 2009卷

关键词：

PPAR-GAMMA AGONISTS; HUMAN T-LYMPHOCYTES; HEPATITIS-C; LIPOPROTEIN METABOLISM; ALPHA; EXPRESSION; ACID; LIGANDS; BEZAFIBRATE; STEATOSIS;

D O I：

10.1155/2009/357204

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The topic of peroxisome proliferator-activated receptors has been developed in the field of hepatology allowing envisaging therapeutic strategies for the most frequent chronic liver diseases such as chronic infection with hepatitis C virus (HCV). PPARs contribute to wide physiological processes within the liver such as lipid/glucid metabolisms, inflammatory response, cell differentiation, and cell cycle. In vitro experiments and animal studies showed that PPAR alpha discloses anti-inflammatory property, and PPAR gamma discloses anti-inflammatory, antifibrogenic, and antiproliferative properties in the liver. Experimental and human studies showed impaired PPARs expression and function during HCV infection. The available nonhepatotoxic agonists of PPARs may constitute a progress in the therapeutic management of patients chronically infected with HCV. Copyright (C) 2009 Sebastien Dharancy et al.

引用

页数：5

共 46 条

[1] Delayed liver regeneration in peroxisome proliferator-activated receptor-α-null mice [J].